0
0
OSAKA, Japan — A new era of precision medicine for psoriasis has moved a significant step closer to reality. Takeda Pharmaceutical Company announced on December 18, 2025, that its investigational oral drug, zasocitinib (formerly TAK-279), successfully met all primary and secondary endpoints in two pivotal Phase 3 clinical trials.
The results from the “Latitude” studies suggest that the once-daily pill could rival the efficacy of injectable biologics, offering a high-clearance, convenient alternative for the millions of adults living with moderate-to-severe plaque psoriasis.
A New Frontier in Precision Design
What distinguishes zasocitinib from previous generations of psoriasis treatments is its origin. The molecule was identified using a “computationally enabled” design strategy—essentially leveraging artificial intelligence and advanced molecular modeling to create a drug with surgical precision.
The drug targets Tyrosine Kinase 2 (TYK2), an enzyme that acts as a gatekeeper for inflammatory signals like Interleukin-23 (IL-23). While other drugs in this class exist, Takeda’s AI-crafted molecule is designed to be “highly selective.” In laboratory assays, zasocitinib demonstrated a 1.3-million-fold greater selectivity for TYK2 compared to related enzymes like JAK1, which are often associated with broader, more systemic side effects.
“These landmark results support zasocitinib’s promise to become a leading oral treatment option,” said Christophe Weber, President and CEO of Takeda, in a statement. “This marks the third positive Phase 3 readout from our pipeline this year, validating our focus on highly selective therapies.”
The Data: Achieving Clear Skin
The two Phase 3 trials, known as Latitude 1 and Latitude 2, enrolled over 1,000 participants globally. The studies compared zasocitinib against both a placebo and apremilast (Otezla), a currently approved oral treatment.
Key findings from the 16-week assessment period include:
-
Rapid Response: Patients saw significant skin improvement as early as week four.
-
High Clearance: More than half (50%+) of participants treated with zasocitinib achieved a PASI 90 response—meaning a 90% reduction in the Psoriasis Area and Severity Index.
-
Total Clearance: Approximately 30% of patients achieved PASI 100, or completely clear skin.
-
Superiority: The drug outperformed both the placebo and the active comparator, apremilast, across all measured categories.
“For many years, the gold standard for ‘clear skin’ was only achievable through regular injections,” explains Dr. April Armstrong, a leading dermatologist and clinical investigator in earlier phases of the drug’s development. “Seeing these types of numbers from a once-daily pill is a potential game-changer for patient quality of life.”
Safety and Tolerability
One of the primary hurdles for oral “small molecule” drugs has been safety. Broader Janus kinase (JAK) inhibitors often carry “boxed warnings” due to risks of blood clots or heart issues. However, because zasocitinib is an allosteric TYK2 inhibitor—meaning it binds to a specific regulatory site on the enzyme rather than the active site shared by other JAKs—it appears to avoid these risks.
In the Phase 3 trials, the safety profile remained consistent with earlier studies. The most common side effects reported were upper respiratory infections, nasopharyngitis (the common cold), and acne. No new or unexpected safety signals were identified during the 24-week follow-up period.
Public Health Implications
Psoriasis affects approximately 125 million people worldwide, including more than 8 million in the United States. Beyond the physical discomfort of itchy, scaly plaques, the condition is a systemic inflammatory disease linked to psoriatic arthritis, cardiovascular disease, and significant mental health challenges.
“The shift toward oral therapies that provide biologic-like clearance is critical for public health,” says Sarah Bloom, a health policy analyst not involved in the study. “Injectables require cold-chain storage and can be intimidating for some patients. An effective pill can increase adherence and broaden access, especially in regions where specialized refrigeration or self-injection training is a barrier.”
Furthermore, Takeda highlighted its “Diversity Action Plan” in these trials, aiming for a participant pool that reflects real-world demographics. This is a crucial step in ensuring that the drug’s efficacy and safety are validated across diverse ethnic and racial backgrounds.
Looking Ahead: The Path to Approval
While the results are robust, medical experts caution that zasocitinib is still an investigational compound. Long-term safety data beyond the initial six months will be necessary to fully understand the drug’s profile, particularly as it moves toward real-world use in millions of patients.
Takeda plans to present full detailed data at upcoming medical congresses and intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and other global regulatory authorities starting in fiscal year 2026.
For patients, the development signals a broader trend in dermatology: the move away from “one-size-fits-all” treatments toward highly specific, AI-optimized molecules that target the root of inflammation while leaving the rest of the immune system intact.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
Study Citations:
-
Takeda Pharmaceutical Company. (2025, December 18). Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill. Press Release.
